The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]


Variant: NM_000314.8(PTEN):c.40A>G (p.Arg14Gly)

CA377781914

427589 (ClinVar)

Gene: PTEN
Condition: PTEN hamartoma tumor syndrome
Inheritance Mode: Autosomal dominant inheritance
UUID: 639b9908-132f-4501-a0b7-d02617eac416

HGVS expressions

NM_000314.8:c.40A>G
NM_000314.8(PTEN):c.40A>G (p.Arg14Gly)
NC_000010.11:g.87864509A>G
CM000672.2:g.87864509A>G
NC_000010.10:g.89624266A>G
CM000672.1:g.89624266A>G
NC_000010.9:g.89614246A>G
NG_007466.2:g.6071A>G
NG_033079.1:g.3929T>C
ENST00000686459.1:c.40A>G
ENST00000688158.1:c.40A>G
ENST00000688308.1:c.40A>G
ENST00000693560.1:c.559A>G
ENST00000371953.8:c.40A>G
ENST00000371953.7:c.40A>G
ENST00000462694.1:n.42A>G
ENST00000487939.1:n.61A>G
ENST00000610634.1:c.-63A>G
ENST00000618586.1:n.9A>G
NM_000314.5:c.40A>G
NM_000314.6:c.40A>G
NM_001304717.2:c.559A>G
NM_001304718.1:c.-666A>G
NM_000314.7:c.40A>G
NM_001304717.5:c.559A>G
NM_001304718.2:c.-666A>G

Uncertain Significance

Met criteria codes 5
PS3_Supporting PP3 PP2 PS4_Supporting PM2_Supporting

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen PTEN Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for PTEN Version 3.0.0

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
PTEN VCEP
NM_000314.8(PTEN):c.40A>G (p.Arg14Gly) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.0.0). Please see a summary of the rules and criteria codes in the “PTEN ACMG Specifications Summary” document (assertion method column). PS4_P: Proband(s) with phenotype specificity score of 1-1.5. (PMID:28526761) PS3_P: Other studies demonstrating lipid phosphatase activity <50% of wild-type or abnormal in vitro cellular assay or transgenic model with phenotype different from wild-type that does not meet PS3_moderate. Mingo et al. 2018 (PMID: 29706633). PM2_Supporting: Absent in large sequenced populations OR present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort. (PMID 27535533). PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease. PP3: in silico REVEL score of 0.811 (>0.7)
Met criteria codes
PS3_Supporting
lipid phosphatase activity <50% of wild-type and aberrant localization (Mingo et al. 2018 PMID: 29706633).
PP3
in silico REVEL score of 0.811 (>0.7)
PP2
missense constraint
PS4_Supporting
Hansen-Kiss et al. 2017 PMID:28526761: Peds score of 6 - Identified in a 4 yo Cauc F proband with macrocephaly 54 cm (+3.9 SD) (2 pts). At age 3 she was diagnosed with hypothyroidism (2 pts), developmental delay, autism (2 pts). Also dx with hypopituitarism and several brown macules (melanocytic nevi) were also identified on scalp, truck/chest, right labia majora; left upper arm. The variant was maternally inherited. The mother has hypothyrodism (dx in 20s) and is macrocephalic (60cm, >98%), Mat GM had thyroid nodules and a thyroidectomy; Mat Aunt hypothyroid. Likely the same proband reported in Frazier et al. 2015.
PM2_Supporting
Absent in gnomAD
Approved on: 2023-08-04
Published on: 2023-10-19
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.